RxDoctor Payments Data

James Gooss

Family · Jal, NMNPI 1578087169

Payments from drug & device makers

$254in general payments, 2019–2025

Across 12 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tactile Systems Technology Inc$46
  • AbbVie$42
  • Pfizer$40
  • Johnson & Johnson$38
  • Boehringer Ingelheim$27
  • Lilly USA, LLC$23
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$254100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$254 in reported general payments places this provider in the 50th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$27,049
Medicare patients
94
Services billed
1,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide14$18,917
MounjaroTirzepatide13$13,405
XareltoRivaroxaban12$13,283
GlyxambiEmpagliflozin/Linagliptin13$7,772
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,486
Tresiba Flextouch U-200Insulin Degludec11$6,939
Xigduo XrDapaglifloz Propaned/Metformin12$6,819
JanumetSitagliptin Phos/Metformin Hcl11$6,127
Spiriva RespimatTiotropium Bromide12$5,961
Breo ElliptaFluticasone/Vilanterol11$4,223
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$1,958
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide26$1,293
Ventolin HfaAlbuterol Sulfate18$1,011
Levothyroxine Sodium65$938
Pravastatin Sodium37$741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$23$32,32227 claims
Boehringer IngelheimGlyxambi, Spiriva Respimat$27$13,73325 claims
Johnson & JohnsonXarelto$38$13,28312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,080 family providers in New Mexico.

Other family in Jal

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →